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of age. Sex was not significantly associated
(mean male to female sex ratio was 32.4:18
for S. typhi and 15.8:10.6 for S. paratyphi A).
S. typhi has become increasingly sensitive to
amoxycillin, chloramphenicol, and gentamicin,
increasing from 75.1% in 1994 to 96.6% in 1998
for amoxycillin, from 71.9% in 1994 to 91.6% in
1998 for chloramphenicol, and from 96.4% to
100% for gentamicin. S. paratyphi A strains have
remained uniformly sensitive (100%) to all
antibiotics (amoxycillin, chloramphenicol, and
gentamicin, as well as ciprofloxacin and
ceftriaxone) used in the treatment of enteric
fever. In light of reports of multidrug resistance
in S. typhi, especially to quinolones, continued
surveillance and monitoring of antimicrobial
sensitivity of S. paratyphi A strains are needed.
The increase in proportion of S. paratyphi A
cases, which may be due to a high degree of
clinical suspicion (with mild fever cases
investigated for enteric fever), changing host
susceptibility, or even change in the virulence of
the organism, should be further investigated.
Seema Sood, Arti Kapil, Nihar Dash,
Bimal K. Das, Vikas Goel, and Pradeep Seth
All India Institute of Medical Sciences,
New Delhi, India
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Hepatitis C Virus RNA Viremia in
Central Africa
To the Editor: Epidemiologic serosurveys have
demonstrated high prevalence (6%-15%) of
hepatitis C virus (HCV) infection in adults in
sub-Saharan Africa (1-4). Although possible
false-positive HCV serologic test results have
been reported in Africa, HCV prevalence rates
suggest a high rate of chronic infection among
persons with anti-HCV antibodies (5,6). We have
focused on HCV RNA infectivity of blood from
donors attending the National Blood Center in
Bangui, Central African Republic.
We prospectively tested all blood donors
between February and April 1998 for serum anti-
HCV antibodies by both an HCV third-
generation enzyme-linked immunosorbent assay
(ELISA) (Abbott HCV EIA 3.0 test, Abbott,
Chicago, IL, USA), which was chosen as a
reference test for immunoglobulin (Ig) G
antibodies to HCV, and by a simple membrane
immunoassay system (Ortho HCV Ab Quik Pack,
Ortho Diagnostic Systems Inc., Tokyo, Japan)
(7).  Anti-HCV-positive serum samples were
further subjected to qualitative detection of HCV
RNA by reverse transcription-polymerase chain
reaction (AMPLICOR-HCV, Roche Diagnostic
Systems, Inc., Branchburg, NJ, USA) (8). Of 163
serum samples (mean age – standard deviation,
30–8 years), 155 were from male blood donors, 83
(51%) from first-time donors, and 125 (77%) from
donors in the recipients family. Fifteen (9.2%;
95% confidence interval [CI] 5%-15%) samples
contained IgG to HCV by ELISA. Of the ELISA-
positive samples, 14 were positive by the Quik
Pack assay (sensitivity, 93.0%); of the 148
remaining ELISA-negative samples, 147 were
negative by the Quik Pack assay (specificity,
99.3%). The agreement between the results of
the two methods was 98.7%. Of the 163 samples,
10 (6.1%; CI 95%: 3%-11%) were positive for HCV
antibodies (by ELISA and rapid test) and for
HCV RNA.
We confirmed a high prevalence of HCV-
seropositivity among blood donors in Bangui and
the subsequent high rate of HCV RNA viremic
blood donations. To offset the major risk for
transfusion-acquired  HCV in Central Africa we
recommend screening donated blood for anti-
HCV. When laboratory facilities to perform
ELISA are not available, the Quik Pack system,
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a simple reliable method for detecting anti-HCV
antibodies in human serum that requires neither
complex reagent preparation nor expensive
instrumentation, could prove useful.
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Immunization of Peacekeeping Forces1
To the Editor: The immunization status of
military contingents arriving from different
nations for peacekeeping missions may vary
widely. This variation results from lack of
information, coordination, and financial support.
For larger missions, the United Nations (UN)
Headquarters issues recommendations about
needed vaccines; recently, operations officers
have consulted World Health Organization
experts before issuing recommendations, and
their advice, which takes into account epidemio-
logic data in the host country, has improved.
Medical officers who develop recommendations
for smaller missions must consider the
pathogenic agent; environment; host efficacy,
safety, and price of preventive measures; and
legal and ethical aspects.
Data on the incidence of vaccine-preventable
diseases within a military population that had
similar duties in the same location are rarely
available. When data from the respective region
are not available, disease incidence or preva-
lence in the host country may be substituted.
These data, however, may be misleading since
the military often does not have the same
lifestyle as the native population. Plague, for
instance, had an incidence rate of 8 per 100,000
in Namibia, but not a single case was reported in
the South African Armed Forces (unpub. SAMS
report: Disease Profile of South West Africa,
1989). If   epidemiologic documentation for a host
country is not available, data from neighboring
countries may be useful.
Travelers diarrhea is the most frequent
health problem abroad (1,2). Although the
diarrhea is self-limited and lasts an average of 1
day with appropriate treatment (4 days without),
the unproductive time may be detrimental to a
military mission. Oral vaccines against the three
most frequent causes of travelers diarrhea
(enterotoxigenic Escherichia coli, Campylobacter
spp., and rotavirus [1,2]) are being developed;
the latter will be available soon (3). Hepatitis A,
most frequent among the vaccine-preventable
diseases (4), is 10 to 100 times more frequent
than typhoid fever (4,5). Hepatitis B occurs
mainly in expatriates, but infections have also
been observed in tourists who have had
unprotected casual sex (6). The incidence rate of
rabies is unknown, but animal bites that may
result in rabies virus transmission and thus
necessitate postexposure prophylaxis are fre-
quent (7). Only anecdotal cases of diphtheria,
tetanus, and tuberculosis have been reported (8).
Poliomyelitis, yellow fever, Japanese encephali-
tis, and plague occur only in limited parts of the
world (5). The situation may rapidly change as
1Presented in part at the NATO Research & Technology Organization, Aerospace Medical Panel Symposium on Aeromedical Support
Issues in Contingency Operations, Rotterdam, The Netherlands, 1 October 1997.
